Galsulfase [Naglazyme]
No
No
No
Active ingredient: Galsulfase
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
Not Applicable
Additional Information
Galsulfase [Naglazyme] is approved for funding under the Rare Disease Fund
This section shows additional information related to the monograph such as drugs that are approved for funding under the Rare Disease Fund.
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Intravenous
* Clinical information is available for this product.
